Diago M - Search Results

1

Hospital admission is a relevant source of hepatitis C virus acquisition in Spain.

Martínez-Bauer E, Forns X, Armelles M, Planas R, Solà R, Vergara M, Fàbregas S, Vega R, Salmerón J, Diago M, Sánchez-Tapias JM, Bruguera M; Spanish Acute HCV Study Group. Martínez-Bauer E, et al. Among authors: diago m. J Hepatol. 2008 Jan;48(1):20-7. doi: 10.1016/j.jhep.2007.07.031. Epub 2007 Oct 12. J Hepatol. 2008. PMID: 17998149

2

Intrafamily transmission of hepatitis C virus: sexual and non-sexual contacts.

Diago M, Zapater R, Tuset C, Carbonell P, Gonzalez C, Cors R, Casas E. Diago M, et al. J Hepatol. 1996 Aug;25(2):125-8. doi: 10.1016/s0168-8278(96)80063-8. J Hepatol. 1996. PMID: 8878771

3

[Indications and prescription of hepatitis A vaccine in Spain. Report of the Spain Association for the Study of the Liver].

Bruguera M, Buti M, Diago M, García Bengoechea M, Jara P, Pedreira JA, Ruiz Extremera A. Bruguera M, et al. Among authors: diago m. Gastroenterol Hepatol. 1997 Nov;20(9):467-73. Gastroenterol Hepatol. 1997. PMID: 9445743 Spanish. No abstract available.

4

[Indications and prescription of hepatitis A vaccine in Spain. Report of the Spanish Association for the Study of the Liver].

Bruguera M, Buti M, Diago M, García Bengoechea M, Jara P, Pedreira JD, Ruiz Estremera A. Bruguera M, et al. Among authors: diago m. Med Clin (Barc). 1998 Sep 26;111(9):341-6. Med Clin (Barc). 1998. PMID: 9810537 Spanish. No abstract available.

5

Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP).

Carreño V, Marcellin P, Hadziyannis S, Salmerón J, Diago M, Kitis GE, Vafiadis I, Schalm SW, Zahm F, Manzarbeitia F, Jiménez FJ, Quiroga JA. Carreño V, et al. Among authors: diago m. Hepatology. 1999 Jul;30(1):277-82. doi: 10.1002/hep.510300117. Hepatology. 1999. PMID: 10385667 Clinical Trial.

6

Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virological response at week 4.

Sánchez-Tapias JM, Crespo J, Diago M, Pérez R, Romero-Gómez M, Muñoz-Sánchez M. Sánchez-Tapias JM, et al. Among authors: diago m. Methods Find Exp Clin Pharmacol. 2002 Nov;24(9):579-84. Methods Find Exp Clin Pharmacol. 2002. PMID: 12616704 Clinical Trial.

7

Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C.

Pérez R, Jiménez M, Crespo J, Diago M, Enríquez J, Vaquero P, Solá R, Olcoz JL, Romero M, Salmerón J, Blanco MI, Oña M, Melón S, Rodrigo L; Grupo Inter-Hospitalario Español. Pérez R, et al. Among authors: diago m. J Viral Hepat. 2003 Nov;10(6):437-45. doi: 10.1046/j.1365-2893.2003.00461.x. J Viral Hepat. 2003. PMID: 14633177 Clinical Trial.

8

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J. Romero-Gómez M, et al. Among authors: diago m. Gastroenterology. 2005 Mar;128(3):636-41. doi: 10.1053/j.gastro.2004.12.049. Gastroenterology. 2005. PMID: 15765399

9

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxì A, Chaneac M, Reddy KR. Ferenci P, et al. Among authors: diago m. J Hepatol. 2005 Sep;43(3):425-33. doi: 10.1016/j.jhep.2005.04.009. J Hepatol. 2005. PMID: 15990196 Clinical Trial.

10

Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*.

González V, Padilla E, Diago M, Giménez MD, Solà R, Matas L, Montoliu S, Morillas RM, Pérez C, Planas R. González V, et al. Among authors: diago m. J Viral Hepat. 2005 Sep;12(5):481-7. doi: 10.1111/j.1365-2893.2005.00628.x. J Viral Hepat. 2005. PMID: 16108762

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

221 results

Search Page